EUVIMEDEUVIMED entdecken
Crossref

SC3613, a Mutant-Selective EGFR Degrader, Demonstrates Improved Safety and Durable Antitumor Activity in Combination with Amivantamab in TKI-Resistant NSCLC

J. Kim, Y.J. Park, O.Y. Lee, C. Lee, W. Lee, K.H. Kim, S. Kim, H.Y. Lee, P.R. Ullapu, M.J. Goo, H. Lee, Y. Oh und 7 weitere

European Journal of Cancer · 2026-11 · 248 · 117618

DOI: 10.1016/j.ejca.2026.117618 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von J. Kim und 18 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Kim, J., Park, Y., Lee, O., Lee, C., Lee, W., Kim, K., Kim, S., Lee, H., Ullapu, P., Goo, M., Lee, H., Oh, Y., Choi, S., Cho, J., Choi, S., Lee, D., Jeon, S., Ryu, K., & Kim, M. (2026). SC3613, a Mutant-Selective EGFR Degrader, Demonstrates Improved Safety and Durable Antitumor Activity in Combination with Amivantamab in TKI-Resistant NSCLC. European Journal of Cancer, 248, 117618. https://doi.org/10.1016/j.ejca.2026.117618

Vancouver

Kim J, Park Y, Lee O, Lee C, Lee W, Kim K, et al. SC3613, a Mutant-Selective EGFR Degrader, Demonstrates Improved Safety and Durable Antitumor Activity in Combination with Amivantamab in TKI-Resistant NSCLC. European Journal of Cancer. 2026;248:117618. doi:10.1016/j.ejca.2026.117618

BibTeX
@article{Kim2026,
  author = {Kim, J. and Park, Y.J. and Lee, O.Y. and Lee, C. and Lee, W. and Kim, K.H. and Kim, S. and Lee, H.Y. and Ullapu, P.R. and Goo, M.J. and Lee, H. and Oh, Y. and Choi, S.H. and Cho, J. and Choi, S.J. and Lee, D.Y. and Jeon, S.H. and Ryu, K.M. and Kim, M.K.},
  title = {SC3613, a Mutant-Selective EGFR Degrader, Demonstrates Improved Safety and Durable Antitumor Activity in Combination with Amivantamab in TKI-Resistant NSCLC},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {248},
  pages = {117618},
  doi = {10.1016/j.ejca.2026.117618}
}
Kostenlos starten →